CR20150476A - Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares - Google Patents

Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares

Info

Publication number
CR20150476A
CR20150476A CR20150476A CR20150476A CR20150476A CR 20150476 A CR20150476 A CR 20150476A CR 20150476 A CR20150476 A CR 20150476A CR 20150476 A CR20150476 A CR 20150476A CR 20150476 A CR20150476 A CR 20150476A
Authority
CR
Costa Rica
Prior art keywords
treatment
oxopyridine
cardiovascular disorders
substituted derivatives
disorders
Prior art date
Application number
CR20150476A
Other languages
English (en)
Spanish (es)
Inventor
Susanne Röhrig
Alexander Hillisch
Julia Strassburger
Stefan Heitmeier
Martina Victoria Schmidt
Karl-Heinz Schlemmer
Adrian Tersteegen
Anja Buchmüller
Christoph Gerdes
Martina Schäfer
Tom Kinzel
Henrik Teller
Hartmut Schirok
Jürgen Klar
Nunez Eloisa Jimenez
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20150476A publication Critical patent/CR20150476A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
CR20150476A 2013-03-28 2015-09-11 Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares CR20150476A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13161588 2013-03-28
EP13190944 2013-10-30
PCT/EP2014/056135 WO2014154794A1 (de) 2013-03-28 2014-03-27 Substituierte oxopyridin-derivate und ihre verwendung bei der behandlung von herz-kreislauf-erkrankungen

Publications (1)

Publication Number Publication Date
CR20150476A true CR20150476A (es) 2016-02-05

Family

ID=50390087

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150476A CR20150476A (es) 2013-03-28 2015-09-11 Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares

Country Status (25)

Country Link
US (3) US9434690B2 (enExample)
EP (1) EP2978756B1 (enExample)
JP (2) JP6266086B2 (enExample)
KR (1) KR20150137095A (enExample)
CN (2) CN105164122B (enExample)
AP (1) AP2015008782A0 (enExample)
AU (1) AU2014242971B2 (enExample)
BR (1) BR112015024414A2 (enExample)
CA (1) CA2908085C (enExample)
CL (1) CL2015002855A1 (enExample)
CR (1) CR20150476A (enExample)
DO (1) DOP2015000246A (enExample)
EA (1) EA028034B9 (enExample)
ES (1) ES2731819T3 (enExample)
MX (1) MX2015013437A (enExample)
NI (1) NI201500143A (enExample)
PE (1) PE20151758A1 (enExample)
PH (1) PH12015502249A1 (enExample)
SG (2) SG11201506879RA (enExample)
TN (1) TN2015000434A1 (enExample)
TW (1) TWI633089B (enExample)
UA (1) UA115902C2 (enExample)
UY (1) UY35508A (enExample)
WO (1) WO2014154794A1 (enExample)
ZA (1) ZA201507155B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
EP3138839B1 (en) * 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
ES2722425T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
EP3197889B1 (de) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046157A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US20190119213A1 (en) * 2015-03-19 2019-04-25 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
FR3046791B1 (fr) * 2016-01-18 2020-01-10 Adisseo France S.A.S. Procede de preparation d'analogues de la methionine
US10633375B2 (en) * 2016-08-31 2020-04-28 Jinagsu Hengrui Medicine Co., Ltd Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
AU2019227332A1 (en) * 2018-02-27 2020-08-27 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of oxopicolinamide derivative and preparation method therefor
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110193012B (zh) * 2018-02-27 2022-02-08 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
ES2920449T3 (es) 2018-03-15 2022-08-04 Bayer Ag Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida
DK3774796T3 (da) 2018-04-10 2022-07-18 Bayer Pharma AG Et substitueret oxopyridinderivat
MX2021007508A (es) * 2018-12-21 2021-08-05 Bayer Ag Derivados de oxopiridina sustituidos.
CA3124296A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
CN112047931B (zh) * 2019-06-06 2024-03-08 上海美悦生物科技发展有限公司 FXIa凝血因子抑制剂、其药物组合物和用途
CN112341377B (zh) * 2019-08-09 2024-05-14 上海美悦生物科技发展有限公司 一种杂环类化合物及其应用
GB201911816D0 (en) * 2019-08-16 2019-10-02 Univ London Queen Mary Treatment
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
CN112940431B (zh) * 2021-02-04 2023-03-10 四川大学 一种激光诱导的荧光发射组合物及图案化荧光发射方法
CN115108977B (zh) * 2021-03-19 2024-11-29 南京正大天晴制药有限公司 一种瑞戈非尼的制备方法
CN114920699B (zh) * 2022-05-31 2024-03-19 甘肃皓天科技股份有限公司 一种制备6-氯-2-甲基-2h-吲唑-5-胺的方法
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178964A1 (en) * 1999-05-19 2002-02-13 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7361672B2 (en) * 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
TW200813017A (en) * 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
JPWO2011077711A1 (ja) * 2009-12-22 2013-05-02 興和株式会社 新規な２−ピリドン誘導体及びこれを含有する医薬
ES2765891T3 (es) * 2011-12-21 2020-06-11 Ono Pharmaceutical Co Derivados de piridinona y pirimidinona como inhibidores del factor XIa
EA025392B1 (ru) * 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани Дигидропиридон р1 в качестве ингибиторов фактора xia
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物

Also Published As

Publication number Publication date
SG11201506879RA (en) 2015-10-29
KR20150137095A (ko) 2015-12-08
CL2015002855A1 (es) 2016-08-26
SG10201710895UA (en) 2018-02-27
US9434690B2 (en) 2016-09-06
CA2908085C (en) 2021-12-28
AP2015008782A0 (en) 2015-10-31
AU2014242971B2 (en) 2018-07-05
NI201500143A (es) 2016-02-16
US20160052884A1 (en) 2016-02-25
TWI633089B (zh) 2018-08-21
EA028034B1 (ru) 2017-09-29
UA115902C2 (uk) 2018-01-10
JP6266086B2 (ja) 2018-01-24
US10183932B2 (en) 2019-01-22
WO2014154794A1 (de) 2014-10-02
EA201591874A1 (ru) 2016-04-29
MX2015013437A (es) 2016-05-18
CN108164513A (zh) 2018-06-15
ZA201507155B (en) 2017-01-25
UY35508A (es) 2014-10-31
TW201524957A (zh) 2015-07-01
BR112015024414A2 (pt) 2017-07-18
US20160368903A1 (en) 2016-12-22
JP6633045B2 (ja) 2020-01-22
TN2015000434A1 (en) 2017-01-03
EP2978756A1 (de) 2016-02-03
CN105164122A (zh) 2015-12-16
EA028034B9 (ru) 2018-02-28
CN108164513B (zh) 2021-05-07
CN105164122B (zh) 2018-02-02
US20180086742A1 (en) 2018-03-29
CA2908085A1 (en) 2014-10-02
PH12015502249A1 (en) 2016-02-01
HK1218749A1 (zh) 2017-03-10
EP2978756B1 (de) 2019-03-27
PE20151758A1 (es) 2015-12-04
JP2018065856A (ja) 2018-04-26
US9822102B2 (en) 2017-11-21
AU2014242971A1 (en) 2015-10-15
DOP2015000246A (es) 2015-11-15
ES2731819T3 (es) 2019-11-19
JP2016515562A (ja) 2016-05-30

Similar Documents

Publication Publication Date Title
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
ECSP18001308A (es) Derivados de oxopiridina sustituidos
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CU20150095A7 (es) Pirimidinas fusionadas sustituidas con trifluorometilo
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.
CR20150631A (es) Benzoxazoles sustituidos
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina